HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Gains in cognition through combined cognitive and physical training: the role of training dosage and severity of neurocognitive disorder.

Abstract
Physical as well as cognitive training interventions improve specific cognitive functions but effects barely generalize on global cognition. Combined physical and cognitive training may overcome this shortcoming as physical training may facilitate the neuroplastic potential which, in turn, may be guided by cognitive training. This study aimed at investigating the benefits of combined training on global cognition while assessing the effect of training dosage and exploring the role of several potential effect modifiers. In this multi-center study, 322 older adults with or without neurocognitive disorders (NCDs) were allocated to a computerized, game-based, combined physical and cognitive training group (n = 237) or a passive control group (n = 85). Training group participants were allocated to different training dosages ranging from 24 to 110 potential sessions. In a pre-post-test design, global cognition was assessed by averaging standardized performance in working memory, episodic memory and executive function tests. The intervention group increased in global cognition compared to the control group, p = 0.002, Cohen's d = 0.31. Exploratory analysis revealed a trend for less benefits in participants with more severe NCD, p = 0.08 (cognitively healthy: d = 0.54; mild cognitive impairment: d = 0.19; dementia: d = 0.04). In participants without dementia, we found a dose-response effect of the potential number and of the completed number of training sessions on global cognition, p = 0.008 and p = 0.04, respectively. The results indicate that combined physical and cognitive training improves global cognition in a dose-responsive manner but these benefits may be less pronounced in older adults with more severe NCD. The long-lasting impact of combined training on the incidence and trajectory of NCDs in relation to its severity should be assessed in future long-term trials.
AuthorsPanagiotis D Bamidis, Patrick Fissler, Sokratis G Papageorgiou, Vasiliki Zilidou, Evdokimos I Konstantinidis, Antonis S Billis, Evangelia Romanopoulou, Maria Karagianni, Ion Beratis, Angeliki Tsapanou, Georgia Tsilikopoulou, Eirini Grigoriadou, Aristea Ladas, Athina Kyrillidou, Anthoula Tsolaki, Christos Frantzidis, Efstathios Sidiropoulos, Anastasios Siountas, Stavroula Matsi, John Papatriantafyllou, Eleni Margioti, Aspasia Nika, Winfried Schlee, Thomas Elbert, Magda Tsolaki, Ana B Vivas, Iris-Tatjana Kolassa
JournalFrontiers in aging neuroscience (Front Aging Neurosci) Vol. 7 Pg. 152 ( 2015) ISSN: 1663-4365 [Print] Switzerland
PMID26300772 (Publication Type: Journal Article)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: